{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"SD/PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"MxR: SD with target lesion regression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"MxR: PD with target lesion regression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"MxR: PR with new lesion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"SD without mixed response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"PD with SPD criteria"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"PD without SPD/MxR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"NE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Patients with Slow Progressive Disease (SPD) status met the following criteria: patient's Eastern Cooperative Oncology Group (ECOG) performance status was 0 or 1, patient's lactate dehydrogenase (LDH) value was not greater than twice the normal upper limit, there was no appearance of visceral metastases other than in the lung, patients did not meet any of the criteria for permanent stopping of study treatment. Mixed response (MxR) criteria was defined as follows: at least 30% decrease in the longest diameter (LD) occurring in at least one target lesion recorded and measured at baseline. Such response occurring in otherwise stable disease (SD) or progressive disease (PD) status of LD of target lesions and without the appearance of one or more new lesions were classified as \"SD with target lesion regression\" or \"PD with target lesion regression\". The appearance of new lesions in otherwise partial response (PR) status of the LD of target lesions were classified as \"PR with new lesion\".","groups":[{"description":"Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.","id":"OG000","title":"NY-ESO 1 Group"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis was performed on the total treated cohort (TTC), which included all subjects who received at least one dose of the Antigen-Specific Cancer Immunotherapeutic (ASCI) treatment.","reportingStatus":"POSTED","timeFrame":"During the study treatment period (maximum duration = 49 months).","title":"Number of Patients With Best Overall Response Including Mixed Response (MxR) and Slow Progressive Disease (SPD) Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}